Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT06637787
Active, not recruiting Observational

Prospective, Explorative, Research Study with Women to Investigate Menstruation Leakage At Night

NCT06637787 · tracked via the Priya Life Science Sweden tracker
Sponsor
Essity Hygiene and Health AB
Phase
Observational
Started
2024-10-16
Last updated
2025-03-19

Condition(s) studied

Menstruation

Investigational drug(s) / intervention(s)

Pads

Pads: A specially desigend pad is used to collect information about leakage and body movement at night.

Study summary

The aim of this study is to investigate why and when menstruation leakages occur during sleep while using protective pads at night. Participants will be asked to use a specially designed pad during menstruation and to answer questions.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Women ≥ 18 years 2. Participant is mentally and physically able to participate in this study 3. Written informed consent to participate in this study 4. Participant with currently heavy menstruations regularly experiencing nocturnal leakages 5. Participant is a regular user of nocturnal menstruation pads 6. Participant is willing to use the prototype pad according to the protocol 7. Willingness to take picture of used pads and transfer to study sponsor anonymously during study duration 8. Available internet connection and device for taking pictures and data transfer (photo upload) 9. Underwear size M or L Exclusion Criteria: 1. Known allergies or intolerances to one or several components of the study prototype 2. Participants without regular menstruation, pregnant or perimenopausal subjects 3. Participants not experiencing nocturnal leakages 4. Participants with pacemakers and/or implant defibrillator or having persons in the household that have a pacemaker and/or implant defibrillator

Primary outcome measure(s)

  • Summary of leakage data of the menstruation pad in correlation with participats movements and position at leakage occasion. — 2025
    Leakage data and body movement will be assessed

Trial sites (1)

FacilityCityRegionStatus
Essity Study site Gothenburg Sweden

More Essity Hygiene and Health AB trials in Sweden

Influence of Dressings on Skin pH Alterations in Simulated Skin Folds in Healthy Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06637787 on ClinicalTrials.gov ↗ ← All trials in Sweden